Compare FAX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FAX | ARVN |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.5M | 600.2M |
| IPO Year | N/A | 2018 |
| Metric | FAX | ARVN |
|---|---|---|
| Price | $12.82 | $7.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $13.93 |
| AVG Volume (30 Days) | 232.6K | ★ 797.9K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | $12.76 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.42 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.60 | $6.97 |
| 52 Week High | $16.37 | $14.22 |
| Indicator | FAX | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 29.61 | 42.54 |
| Support Level | N/A | N/A |
| Resistance Level | $14.72 | $8.52 |
| Average True Range (ATR) | 0.26 | 0.32 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 17.48 | 33.10 |
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.